Главная страницаLBank Stocks
Веревулф Терапьютикс Инк.
Веревулф Терапьютикс Инк.

Веревулф Терапьютикс Инк. (HOWL)

24HВысокий$1.0524HНизкий$0.86
$0.88
-0.11%

Последнее обновление: 2026-08-25 10:18:16

Симуляция графика K-линий, фактические данные указаны на торговой странице

Ключевые данные

Открытие вчера
$0.98
Пред. закрытие
$0.88
Вчерашний диапазон
$0.86 - $1.05
Диапазон 52 нед.
$0.27 - $2.38
Объем торговли
182.988M
МС
$42.451M
P/E
--
EPS
$-0.73

Обзор компании

NASDAQ

Werewolf Therapeutics, Inc., биофармацевтическая компания, разрабатывает методы лечения, предназначенные для стимуляции иммунной системы организма для борьбы с раком. Штаб-квартира компании находится в Кембридже, штат Массачусетс.

СекторЗДРАВООХРАНЕНИЕ
ОтрасльБИОТЕХНОЛОГИИ
Штаб-квартира200 ТАЛКОТТ АВЕНЮ, УОТЕРТАУН, МА, СОЕДИНЕННЫЕ ШТАТЫ, 02472
СтранаСША
Дата листинга2021-04-30
Конец финансового года2026-06-30
Акции в обращении48.599M
Код CIK1785530

Финансовые показатели

Индикатор2026-06-302026-03-312025-12-312025-09-30
Доход$21M$0$0$0
Операционные расходы$2.452M$398K$400K--
Чистая прибыль$3.67M-$13.532M-$8.381M-$16.37M
Чистая рентабельность17.5%------
Прибыль на акцию--------
EBITDA$10.989M-$11.766M-$6.612M-$14.627M
Эффективная налоговая ставка--------

Часто задаваемые вопросы

HOWL operates in the [sector] sector and specializes in [industry-specific services/products]. The company focuses on [core business activities], making it a key player in its respective field. Investors often look at HOWL for its ability to drive revenue through [key revenue drivers].
HOWL primarily generates revenue through [specific business operations or product sales detailed in its profile]. These activities are central to its business model and drive growth within the [sector] sector. Understanding these revenue sources can help investors evaluate the company's financial health.
HOWL faces competition from [list key competitors or types of companies if specifics are unavailable]. These rivals operate in the same [sector/industry] and compete in areas like [specific metrics such as pricing, innovation, or market share]. Investors should analyze how HOWL differentiates itself from these competitors.
Investing in HOWL involves risks such as [industry-specific risks], competitive pressures, and potential macroeconomic factors like [highlight economic influences]. Additionally, risks unique to HOWL’s operations could impact its profitability and market performance over time.
Currently, HOWL [does/does not] provide dividends to its shareholders. Investors who prioritize income-focused strategies should consider this in their portfolio decisions. Dividend policies are typically influenced by the company's earnings performance and financial strategy.
HOWL's growth potential lies in [specific opportunities such as expansion into new markets, product innovation, or industry trends]. Additionally, favorable trends in the [sector] could provide a platform for sustained growth. However, investors need to weigh opportunities against inherent industry and company-specific risks.
HOWL’s valuation can be compared using metrics like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, or other industry benchmarks. These metrics help investors determine whether the stock is undervalued or overvalued relative to its sector peers. HOWL’s performance must also be evaluated alongside broader market conditions.
Analysts and investors focus on HOWL’s ability to maintain or grow revenue, manage costs, and respond to market trends. Financial performance indicators such as earnings, profit margins, and future projections are key areas of interest. However, differing opinions highlight the importance of independent research.
Предупреждение о рисках
  1. 1.Цены на акции могут сильно колебаться, инвестируйте осторожно. Прошлые результаты не гарантируют будущую доходность.
  2. 2.Торговля цифровыми активами сопряжена с рыночными, техническими и иными рисками. Пожалуйста, принимайте взвешенные решения и рационально распределяйте активы.
  3. 3.Информация на этой странице предназначена только для ознакомления и не является инвестиционной рекомендацией.